Baltimore Biotech Developing Diabetes Treatments Raises $20.5M
Glyscend Incorporated, a Baltimore-based biotechnology company out of Johns Hopkins University, has raised $20.5M in Series A funding to develop treatments for Type 2 Diabetes. According to theBaltimore Business Journal, the startup has been developing technologies that aim to recreate the effects of bariatric surgery for patients dealing with diabetes and obesity without the need for invasive procedures.